Evidence map›Paper›PMID 34455628›Full record

ArticleProteins2022

A multiscale approach to predict the binding mode of metallo beta-lactamase inhibitors.

Silvia Gervasoni, James Spencer, Philip Hinchliffe, Alessandro Pedretti, Franco Vairoletti, Graciela Mahler, Adrian J Mulholland

Open access · hybridAbstract read
In one paragraph

Article in Proteins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Silvia GervasoniDepartment of Pharmaceutical Sciences, University of Milan, Milan, Italy.ORCID 0000-0002-5731-3396
James SpencerSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.ORCID 0000-0002-4602-0571
Philip HinchliffeSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.ORCID 0000-0001-8611-4743
Alessandro PedrettiDepartment of Pharmaceutical Sciences, University of Milan, Milan, Italy.ORCID 0000-0001-5916-2029
Franco VairolettiFacultad de Química, Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Universidad de la República (UdelaR), Montevideo, Uruguay.ORCID 0000-0002-5160-2250
Graciela MahlerFacultad de Química, Departamento de Química Orgánica, Laboratorio de Química Farmacéutica, Universidad de la República (UdelaR), Montevideo, Uruguay.ORCID 0000-0003-0612-0516
Adrian J MulhollandSchool of Chemistry, University of Bristol, Bristol, UK.ORCID 0000-0003-1015-4567
University of Bristol · GBUniversidad de la República de Uruguay · UYUniversity of Milan · IT

Funding

A Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4M
Biotechnology and Biological Sciences Research Council BB/L01386X/1Medical Research Council MR/T016035/1NIAID NIH HHS R01 AI100560
6 · The paper itself

Abstract

Antibiotic resistance is a major threat to global public health. β-lactamases, which catalyze breakdown of β-lactam antibiotics, are a principal cause. Metallo β-lactamases (MBLs) represent a particular challenge because they hydrolyze almost all β-lactams and to date no MBL inhibitor has been approved for clinical use. Molecular simulations can aid drug discovery, for example, predicting inhibitor complexes, but empirical molecular mechanics (MM) methods often perform poorly for metalloproteins. Here we present a multiscale approach to model thiol inhibitor binding to IMP-1, a clinically important MBL containing two catalytic zinc ions, and predict the binding mode of a 2-mercaptomethyl thiazolidine (MMTZ) inhibitor. Inhibitors were first docked into the IMP-1 active site, testing different docking programs and scoring functions on multiple crystal structures. Complexes were then subjected to molecular dynamics (MD) simulations and subsequently refined through QM/MM optimization with a density functional theory (DFT) method, B3LYP/6-31G(d), increasing the accuracy of the method with successive steps. This workflow was tested on two IMP-1:MMTZ complexes, for which it reproduced crystallographically observed binding, and applied to predict the binding mode of a third MMTZ inhibitor for which a complex structure was crystallographically intractable. We also tested a 12-6-4 nonbonded interaction model in MD simulations and optimization with a SCC-DFTB QM/MM approach. The results show the limitations of empirical models for treating these systems and indicate the need for higher level calculations, for example, DFT/MM, for reliable structural predictions. This study demonstrates a reliable computational pipeline that can be applied to inhibitor design for MBLs and other zinc-metalloenzyme systems.

Indexed as

Anti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-Lactamasesbeta-LactamsCatalytic DomainModels, MolecularZincAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-Lactamasesbeta-LactamsZincantibiotic resistanceIMP-1MBL inhibitormetalloenzymesmetallo β-lactamasesthiazolidinezinc enzymes

Identifiers

PMID34455628
PMCPMC8944931
OpenAlexW3198416755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.